USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
Novel Inhaler Devices and Formulations are Impetuses for Growth
30-Oct-2014
North America
Market Research
MA2A-01-00-00-00
LS00101-NA-MR_16942
The research service assesses marketed and investigational products, as well as combination regimens, for asthma and chronic obstructive pulmonary disease (COPD). Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology. The marketed and pipeline products are broadly segmented into bronchodilators, anti-inflammatories, and combination therapies of current global interest. Novel inhaler devices, formulations, and anti-inflammatories are key drivers for the market.
Key Findings
Key Findings—Asthma
Key Findings—COPD
Overview of Product Launches and Pipeline Development
Key Companies to Watch
CEO’s Perspective
Methodology and Scope
Market Overview—Segmentation
Market Overview—Definitions
Prevalence of Asthma by Country/Region
Prevalence of COPD by Country/Region
Asthma Therapeutics Market—Marketed and Pipeline Products
Asthma Therapeutics Market—Marketed and Pipeline Products (continued)
Asthma Therapeutics Market—Key Marketed Product Synopsis
Asthma Therapeutics Market—Key Marketed Product Synopsis (continued)
Asthma Therapeutics Market—Key Pipeline Product Synopsis
Asthma Therapeutics Market—Key Pipeline Product Synopsis (continued)
COPD Therapeutics Market—Marketed and Pipeline Products
COPD Therapeutics Market—Marketed and Pipeline Products (continued)
COPD Therapeutics Market—Key Marketed Product Synopsis
COPD Therapeutics Market—Key Marketed Product Synopsis (continued)
COPD Therapeutics Market—Key Pipeline Product Synopsis
COPD Therapeutics Market—Key Pipeline Product Synopsis (continued)
Total Asthma and COPD Therapeutics Market—Projected Launch Timeline for Key Pipeline Drugs
Pivotal Phase 3 Trials
Estimated Product Launch Timeline—Striverdi Respimat for Asthma and COPD by Boehringer Ingelheim
Estimated Product Launch Timeline—Quilizumab for Asthma by Genentech
Estimated Product Launch Timeline—DuoResp Spiromax for Asthma and COPD by Teva Pharmaceuticals
Estimated Product Launch Timeline—Incruse Ellipta (umeclidinium) for COPD by GSK
Estimated Product Launch Timeline—Benralizumab for Asthma by AstraZeneca
Patent Expiration Timeline
Seebri Breezhaler by Novartis
Advair/Seretide by GSK
Xolair by Genentech and Novartis
Asmanex Twisthaler by Merck & Co.
Spiriva by Boehringer Ingelheim
AirFlu Sal/Forspiro by Sandoz (Novartis)
Incruse Ellipta by GSK
Benralizumab by AstraZeneca
Bosatria by GSK
PT003 by Pearl Therapeutics (AstraZeneca)
Conclusions
Legal Disclaimer
Decision Support Database—Global Prevalence of Smokers
Decision Support Database—Global Prevalence of Smokers (continued)
Decision Support Database—Population with COPD
Decision Support Database—Population with COPD (continued)
The Frost & Sullivan Story
Value Proposition: Future of Your Company & Career
Global Perspective
Industry Convergence
360º Research Perspective
Implementation Excellence
Our Blue Ocean Strategy
Speak directly with our analytics experts for tailored recommendations.
Recent related Life Sciences research
13 Jan 2025 | Global | Market Outlook
Top 6 Growth Opportunities for the Digital Health Industry, 2025
Driven by digital advancements, the healthcare industry is transforming rapidly. Current trends and challenges create constant change, and industry stakeholders must adapt to remain attractive, competitive, and unique as robust organizations. Each year, competitors must gain a fresh, comprehensive v...
17 Dec 2024 | Global | Market Research
Cybersecurity in Healthcare, United States, 2024
Healthcare is the industry most affected by cyberattacks, which have targets like hospitals, healthcare organizations, patient databases, and connected devices. These attacks not only destabilize healthcare systems but also threaten care delivery and patient safety. The global healthcare infrastruct...
12 Dec 2024 | Global | Market Outlook
Top 6 Growth Opportunities for Clinical Diagnostics, Global, 2025
Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and trans...
05 Dec 2024 | Global | Frost Radar
Frost Radar™: Enterprise Conversational AI in Healthcare, 2024
This Frost Radar™ benchmarks the companies and their solutions that allow healthcare payers and providers to create next-generation virtual assistants. Conversational AI is primarily used to streamline patient and provider processes and interactions across the care continuum—the pre-care, at-care, a...
27 Nov 2024 | Global | Market Research
Generative AI in Payer and Provider IT Transformation, Global, 2024-2029
The healthcare payer and provider industry is gradually adopting generative artificial intelligence (Gen AI) solutions across its value chain. Almost all organizations have shown an intent to implement Gen AI-based solutions in their products or processes, with a few already embarking on this journe...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
| Deliverable Type | Market Research |
|---|---|
| No Index | No |
| Podcast | No |
| Author | Sriram Radhakrishnan |
| WIP Number | MA2A-01-00-00-00 |
| Is Prebook | No |
A Competitive Analysis of the Global Asthma and COPD Therapeutics Market
$3,950.00
Special Price $2,962.50 save 25 %